| Genentech USA |
50242009601 |
Vabysmo 6mg/0.05ml Vial |
2022-02-08 |
2190.0000 |
Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers and - in some cases - patients about the approved indication(s), efficacy and safety data contained within the medicine's FDA approved label.
We take decisions related to the prices of our medicines very seriously. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines getting to people who need them. |
None |
80000 |
None |
None |
None |
None |
None |
None |
Estimated number of patients for Vabysmo is per year. Vabysmoo was not acquired from a 3rd party |
None |
| GlaxoSmithKline |
00173090442 |
NUCALA, Injection, 40 mg/0.4mL, 1 Syringe in 1 Carton |
2022-06-22 |
1330.1400 |
None |
1 |
300000 |
None |
None |
None |
None |
None |
None |
NUCALA (NDC: 001730090442) is a 40 mg prefilled syringe approved for appropriate children aged 6 to 11 years old who have severe eosinophilic asthma (SEA). Asthma is the most common chronic disease in children. It is estimated that 6 million children in the US are living with asthma. Approximately 2.5-5% (150,000-300,000) of these cases are characterized as severe. Diagnosed patients may or may not be prescribed NUCALA (NDC: 00173090442) depending on their known resistance to the medicines and other patient specific factors such as allergic reactions or other medical conditions that may preclude a patient's ability to be effectively treated with NUCALA (NDC: 00173090442).
GSK has not released NUCALA's (NDC: 00173090442) marketing or pricing plan information in the public domain and is limiting its response to that which is publicly available pursuant to California Code of Regulations, Title 22, Division 7, Chapter 9.5 Section 96076(c). |
None |
| GlaxoSmithKline |
58160082415 |
PRIORIX, Single dose vial, 0.5mL, package size: 10 |
2022-08-02 |
873.1400 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
GSK has not released PRIORIX's (NDC: 58160-0824-15) marketing or pricing plan information in the public domain and is limiting its response to that which is publicly available pursuant to California Code of Regulations, Title 22, Division 7, Chapter 9.5 Section 96076(c).
GSK is limiting its response to information that which is otherwise in the public domain or publicly available per California Code of Regulations, Title 22, Division 7, Chapter 9.5 Section 96076(c). We are unable to identify specific and accurate information in the public domain regarding the estimated volume of patients who may be prescribed Priorix (NDC:58160082415) for Measles, Mumps, Rubella. According to the CDC, roughly 90% of children under 24 months are vaccinated against mumps, measles, rubella (MMR), and there are roughly 3.6 million births per year. PRIORIX is approved for administration at 12 through 15 months of age for the first dose and at 4 through 6 years of age for the second dose.
https://www.cdc.gov/nchs/data/vsrr/vsrr012-508.pdf
https://www.cdc.gov/nchs/fastats/measles.htm |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462088260 |
Abiraterone Acetate oral tablets 500 mg, 120 count |
2022-06-22 |
4219.5400 |
None |
1 |
45309 |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, however IQVIA MAT data for the 12 months ending May 2022 is 45,309 prescriptions for 500 mg. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462016630 |
Fingolimod Capsules 0.5 mg, 30 |
2022-10-31 |
1000.0000 |
None |
1 |
182150 |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, however IQVIA MAT data for the 12 months ending September 2022 is 182,150 prescriptions. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462085320 |
Sodium Phenylbutyrate Tablets 500mg, 250 |
2022-11-22 |
3000.0000 |
None |
1 |
1760 |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, however IQVIA MAT data for the 12 months ending September 2022 is 1,760 prescriptions. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Global Blood Therapeutics, Inc. |
72786011102 |
Oxbryta 300mg Tablets for Oral Suspension 60-Count Bottle |
2022-01-10 |
10417.0000 |
(a)Description of the marketing used in the introduction of the new prescription drug:
Marketing efforts used by Global Blood Therapeutics, Inc. (GBT) in the introduction of OXBRYTA currently include direct-to-consumer advertising through print materials, web-based mediums, in-person patient ambassador programs and radio. In addition, GBT participates in patient-focused conferences and events. GBT does not currently plan to conduct direct-to-consumer advertising of OXBRYTA through television.
GBT will offer a free drug program for qualifying patients. Aside from such program, GBT does not plan to provide direct-to-consumer promotional incentives that are different from GBT’s “patient assistance programs”
GBT will educate health care providers about OXBRYTA through in-office visits by GBT representatives, direct mailings, educational speaker programs, promotion at large conferences and conventions as well as web-based mediums. GBT will distribute educational materials to health care providers regarding OXBRYTA, including medical journal articles about the drug.
GBT does not plan to offer product samples for OXBRYTA, and will not provide any “gifts” to health care providers. (b) Methodology used to establish the price of the new prescription drug:
Global Blood Therapeutics, Inc. (GBT) does not conceptualize its pricing decisions by considering a specific set of financial and/or non-financial factors. A range of considerations impacted its decision to set the wholesale acquisition cost for OXBRYTA. The following list of financial and nonfinancial factors reflects its good faith effort to articulate the considerations that impacted its pricing decision:
• The direct and indirect cost and burden of sickle cell disease in the patient population for which OXBRYTA is indicated and the prevalence of the disease.
• The value and impact of OXBRYTA for patients, their families and society, including its clinical benefit relative to existing treatments for sickle cell disease, and the anticipated cost savings GBT’s believes OXBRYTA will bring to the health care system.
• The impact on net revenues, and the need to fund operations, which includes production, supply, and other operational and administrative costs.
• GBT’s commitment to and investment in developing medicines for sickle cell disease, including costs associated with developing OXBRYTA, as well as anticipated future investments in research and development.
• The results of GBT’s extensive research with patients, physicians and payers, including regarding stakeholder perceptions and potential government and commercial payer coverage for OXBRYTA.
• The price of OXBRYTA as compared to treatments for other orphan drugs, which require a significant investment for a smaller eligible patient population. |
None |
16000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Global Blood Therapeutics, Inc. |
72786011103 |
Oxbryta 300mg Tablets for Oral Suspension 90-Count Bottle |
2022-01-10 |
10417.0000 |
(a)Description of the marketing used in the introduction of the new prescription drug:
Marketing efforts used by Global Blood Therapeutics, Inc. (GBT) in the introduction of OXBRYTA currently include direct-to-consumer advertising through print materials, web-based mediums, in-person patient ambassador programs and radio. In addition, GBT participates in patient-focused conferences and events. GBT does not currently plan to conduct direct-to-consumer advertising of OXBRYTA through television.
GBT will offer a free drug program for qualifying patients. Aside from such program, GBT does not plan to provide direct-to-consumer promotional incentives that are different from GBT’s “patient assistance programs”.
GBT will educate health care providers about OXBRYTA through in-office visits by GBT representatives, direct mailings, educational speaker programs, promotion at large conferences and conventions as well as web-based mediums. GBT will distribute educational materials to health care providers regarding OXBRYTA, including medical journal articles about the drug.
GBT does not plan to offer product samples for OXBRYTA, and will not provide any “gifts” to health care providers. (b) Methodology used to establish the price of the new prescription drug:
Global Blood Therapeutics, Inc. (GBT) does not conceptualize its pricing decisions by considering a specific set of financial and/or non-financial factors. A range of considerations impacted its decision to set the wholesale acquisition cost for OXBRYTA. The following list of financial and nonfinancial factors reflects its good faith effort to articulate the considerations that impacted its pricing decision:
• The direct and indirect cost and burden of sickle cell disease in the patient population for which OXBRYTA is indicated and the prevalence of the disease.
• The value and impact of OXBRYTA for patients, their families and society, including its clinical benefit relative to existing treatments for sickle cell disease, and the anticipated cost savings GBT’s believes OXBRYTA will bring to the health care system.
• The impact on net revenues, and the need to fund operations, which includes production, supply, and other operational and administrative costs.
• GBT’s commitment to and investment in developing medicines for sickle cell disease, including costs associated with developing OXBRYTA, as well as anticipated future investments in research and development.
• The results of GBT’s extensive research with patients, physicians and payers, including regarding stakeholder perceptions and potential government and commercial payer coverage for OXBRYTA.
• The price of OXBRYTA as compared to treatments for other orphan drugs, which require a significant investment for a smaller eligible patient population. |
None |
16000 |
None |
None |
None |
None |
None |
None |
None |
None |